ReviewDrugs2010
Triptans for the management of migraine.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.Cephalalgia : an international journal of headache · 2019Guideline
- Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.The Cochrane database of systematic reviews · 2014Pooled it
- An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients.Journal of pharmacokinetics and pharmacodynamics · 2018Trial
- Trial
- Theory-based analysis of clinical efficacy of triptans using receptor occupancy.The journal of headache and pain · 2014Trial
- Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012Trial
- A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.The journal of headache and pain · 2011Trial
- Targeting GCell reports. Medicine · 2026Article
- Artificial intelligence in migraine: a narrative review on the diagnostic, prognostic, and therapeutic applications.Oxford open neuroscience · 2026Article
- Transforming Amino Acids into Serotonin 5-HTJournal of the American Chemical Society · 2025Article
- Pharmacologic and Nonpharmacologic Pain Management in Patients with Traumatic Brain Injury: A Multidisciplinary Approach.Journal of clinical medicine · 2025Review
- Health equity, care access and quality in headache - part 2.The journal of headache and pain · 2023Review
- Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.British journal of clinical pharmacology · 2019Review
- Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine.Brain sciences · 2019Article
- Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice.Cephalalgia : an international journal of headache · 2019Article
- Review
- Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine.Medical devices (Auckland, N.Z.) · 2018Review
- The presenting and prescribing patterns of migraine in an Australian emergency department: A descriptive exploratory study.World journal of emergency medicine · 2017Article
- Development of a measure of self-efficacy for acute headache medication adherence.Journal of behavioral medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a chronic, recurrent, disabling condition that affects millions of people in the US and worldwide. Proper acute care treatment for migraineurs is essential for a full return of function and productivity. Triptans are serotonin (5-HT)(1B/1D) receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available in every country, with multiple routes of administration, giving doctors and patients a wide choice. Despite the similarities of the available triptans, pharmacological heterogeneity offers slightly different efficacy profiles. All triptans are superior to placebo in clinical trials, and some, such as rizatriptan 10 mg, eletriptan 40 mg, almotriptan 12.5 mg, and zolmitriptan 2.5 and 5 mg are very similar to each other and to the prototype triptan, sumatriptan 100 mg. These five are known as the fast-acting triptans. Increased dosing can offer increased efficacy but may confer a higher risk of adverse events, which are usually mild to moderate and transient in nature. This paper critically reviews efficacy, safety and tolerability for the different formulations of sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, eletriptan and frovatriptan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.